Tatva Chintan Pharma Chem Ltd has scheduled a virtual one-on-one meeting with Valcore Capital Advisors for June 17, 2026. The company stated that the interaction will focus on publicly available information and no unpublished price sensitive information (UPSI) will be shared during the discussion.

The meeting details were submitted to the exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company noted that the schedule is subject to change.

Meeting Schedule

Ishwar Nayi, Company Secretary and Compliance Officer, signed the intimation on June 12, 2026.

Promoters of tatva chintan pharma have confirmed that no shares of the company were encumbered directly or indirectly during the financial year ended March 31, 2026. The declaration, submitted to the stock exchanges, assures stakeholders that the promoter group has not pledged any holdings during this period, thereby mitigating potential risks associated with promoter pledging.

The disclosure was filed on April 1, 2026, pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Shekhar Rasiklal Somani, a promoter of the company, made the declaration on behalf of himself and other persons acting in concert. The filing was addressed to the Corporate Relationship Department of BSE Limited and the Listing Department of National Stock Exchange of India Limited.

The promoter group comprises 13 entities, including individuals and corporate bodies. The list includes Shekhar Rasiklal Somani, Kajalben Shekharkumar Somani, and Shitalbhai Rasiklal Somani. Other members include Somani Samir Rasiklal, Aryan Shekhar Somani, Sweny Shekhar Somani, and Archana Chandresh Shah. The group also features Dipali Nitinkumar Mehta and Samir Rasiklal HUF Somani.

Corporate entities within the promoter group include Arete Virtue Jewels, Bakia Laboratories, and Sardar Medical. Additionally, Shekhar Rasiklal Somani Ancestral and Shital R Somani Ancestral are listed as part of the group. The declaration confirms that none of these entities have created any encumbrance on the company's shares during FY26.

A copy of the declaration has been marked to the Chairman and the Audit Committee of the Board of Directors of Tatva Chintan Pharma Chem Limited. The company operates from its registered office located at Plot No 502/17, GIDC Estate, Ankleshwar, Dist. Bharuch, Gujarat.